an injectable pro-drug form of the COX2 selective inhibitor, valdecoxib.
the first parenteral COX-2 selective inhibitor available for clinical use in pain management
onset of action after IM / IV dose is 7-13 minutes with analgesia commencing 23-39 minutes and peaking at under 2 hours
duration of analgesia after a single dose is 6-12 hours and gives longer duration analgesia than
ketorolacelimination half life of valdecoxib is 8hrs and 70% is excreted in kidneys. Metabolism includes cytochrome P450 3A4 and 2C9, so there is a potential for interaction with drugs which inhibit or induce these enzymes.
has only been approved for use as a single perioperative injection so most of the safety data refer to single doses
may increase incidence of heart attacks after heart surgery and rarely can cause SJS although a 2017 pooled analysis of safety data in 28 published studies, which showed after 69,567,300 units of parecoxib, skin rash and cardiac complications were minimal, if at all, different from placebo.